Western Superconducting Technologies (SHA:688122) subsidiary Xi'an Juneng Superconducting Magnet Technology is looking to launch an IPO on the Beijing Stock Exchange, according to a Tuesday filing with the Shenzhen bourse.
Juneng Magnet is looking to issue 25 million shares, with an overallotment option for up to 3.8 million shares.
The subsidiary will use the proceeds, set at 301.9 million yuan, to fund its superconducting magnet production and research center projects.
Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received the approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci136.The drug is indicated for autoimmune disease myasthenia gravis, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.
Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci145 tablets.The drug is indicated for locally advanced or metastatic solid tumors with PIK3CA mutations, which occur in 30% to 40% of breast cancers, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.
Suzhou Zelgen Biopharmaceuticals (SHA:688266) presented two cancer drugs at the American Society of Clinical Oncology, according to a Shanghai bourse filing on Tuesday.The drugs presented were Nilvanstomig, which was developed as a treatment for hepatocellular carcinoma, and Alveltamig, a T-cell engager immunotherapy.Both drugs showed safety profiles during the clinical trials.